We are pleased to have been chosen by Prochon as its partner to provide clinical manufacturing services
Toronto, ON (Vocus) June 21, 2010
Therapure Biopharma Inc. today announced an agreement under which Therapure will provide manufacturing services for ProChon Biotech, a specialty pharmaceutical company based in Israel with an executive management team based in Woburn, MA. Under the terms of the agreement, Therapure will provide services to support clinical manufacturing for one of ProChon’s products, which may be used for articular cartilage regeneration. The companies are also negotiating contracts for on-going manufacturing services, subject to the product achieving FDA approval. Financial terms were not disclosed.
ProChon Biotech Limited (Prochon) is a privately owned biotechnology company focused on providing products for articular cartilage regeneration. Prochon’s expertise in modulating the fibroplast growth factor (FGF) enables it to create more effective solutions for tissue regeneration.
“We are pleased to have been chosen by Prochon as its partner to provide clinical manufacturing services” said Thomas Wellner, President and CEO of Therapure. “Therapure has performed these services for a number of clients and has demonstrated market leading expertise.” continued Mr. Wellner.
“We believe that Therapure has the most relevant expertise for successful implementation of our manufacturing requirements.” said Patrick O’Donell, CEO of Prochon Inc.
About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.
For more information, please visit: http://www.therapurebio.com
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204